The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).
 
Katrin Marie Sjoquist
Honoraria - Pfizer
Travel, Accommodations, Expenses - Amgen; Ipsen
 
Nick Pavlakis
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche; Specialised Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche; Sanofi; Specialised Therapeutics
 
Andrew James Martin
No Relationships to Disclose
 
Eric Tsobanis
No Relationships to Disclose
 
Sonia Yip
Honoraria - Lilly
 
Yung-Jue Bang
Consulting or Advisory Role - Bayer
Research Funding - Bayer
 
Thierry Alcindor
Consulting or Advisory Role - Amgen; Lilly; Novartis Canada Pharmaceuticals Inc
Research Funding - CytRx Corporation (Inst); Eisai (Inst); Epizyme (Inst); Lilly (Inst)
 
Christopher J. O'Callaghan
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Novartis; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Glenmark; Lilly; Merrimack; NCCN; Regeneron; Research to Practice; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Expert Testimony - Helsinn Therapeutics
Other Relationship - ARMO BioSciences; Exelixis; Exelixis; Merck; Polaris; Sillajen
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Li-Tzong Chen
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Merrimack; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha enolase ENO 1 monoclonal antibody/HuniLife
 
John Simes
No Relationships to Disclose
 
John Raymond Zalcberg
Honoraria - Amgen; Bayer; Merck Serono; pfizer; Roche; Specialised Therapeutics
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Pfizer; Roche; Specialised Therapeutics
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Shire (Inst)
Travel, Accommodations, Expenses - Ipsen; Merck Serono
 
David Goldstein
Stock and Other Ownership Interests - Sirtex Medical
Research Funding - Amgen (Inst); Bayer (Inst); celgene (Inst); pfizer (Inst)